Novartis Newswire

Novartis Newswire

Comprehensive Real-Time News Feed for Novartis.

Results 1 - 20 of 55 in Novartis

  1. Report: Stamford pharma deal could hit $700mRead the original story w/Photo

    Monday Jun 29 | Norwalk Citizen News

    Spinifex Pharma, led the past 10 years by CEO Tom McCarthy, is being acquired by Novartis for $200 million up front, and reportedly as much in $500 million in future payments depending on milestones the pain medication company achieves. Photo: Alexander Soule / Alexander Soule Swiss giant Novartis is acquiring Stamford-based Spinifex Pharmaceuticals , a 20-person startup developing drugs to treat chronic pain, in a deal worth as much as $700 million.

    Comment?

  2. Drugmakers warn Greek medicine supply 'may be in jeopardy'Read the original story w/Photo

    Monday Jun 29 | Channelnewsasia.com

    ... steps are taken to stop the diversion of supplies to other countries. Bergstrom said global companies like Roche , Novartis , Pfizer and Sanofi wanted to find a way to keep drugs flowing but needed support from the European Commission. If Greece ...

    Comment?

  3. Must Watch Stocks for June 29, 2015Read the original story w/Photo

    Monday Jun 29 | Benzinga

    ... for C$8.6 billion ($6.98 billion) in cash. GE shares fell 1.03 percent to $26.82 in after-hours trading. Novartis AG (ADR) (NYSE: NVS ) agreed to buy U.S.-Australian company Spinifex Pharmaceuticals. Novartis shares slipped 0.81 percent to close at ...

    Comment?

  4. I Would Avoid The Broader Swiss Market For Now, But Swiss...Read the original story w/Photo

    Sunday Jun 28 | Seeking Alpha

    While the Swiss Market Index would be boosted by a weaker franc, this is unlikely to take place for some time. However, Swiss pharmaceutical companies Novartis AG and Roche Holding AG appear to be significantly undervalued with high earnings potential.

    Comment?

  5. Building The Core With Vanguard: Foreign StocksRead the original story w/Photo

    Tuesday Jun 23 | Seeking Alpha

    ... the largest portions of the fund, here are extremely brief synopses of the Top two; Nestle SA ( OTCPK:NSRGY ) and Novartis AG (NYSE: NVS ): Nestle SA - Nestle is the largest food company in the world , measured by revenues. Encompassing baby food, ...

    Comment?

  6. Argos Therapeutics, Inc. Hires As Vice President Of Corporate Communications And Investor RelationsRead the original story

    Sunday Jun 14 | BioSpace

    ... of experience in the investor and corporate communications field. He has served as director, investor relations at Novartis Corporation and senior director at Medco Health Solutions. He has also spent a number of years as a communications ...

    Comment?

  7. Argos Therapeutics Hires John D. Menditto as Vice President of...Read the original story w/Photo

    Monday Jun 15 | GlobeNewswire

    ... of experience in the investor and corporate communications field. He has served as director, investor relations at Novartis Corporation and senior director at Medco Health Solutions. He has also spent a number of years as a communications ...

    Comment?

  8. Roche On The Wrong Side For Once In Shifting Analyst ForecastsRead the original story w/Photo

    Saturday Jun 6 | Seeking Alpha

    Roche's reputation as a peerless R&D powerhouse has taken a battering in the past year, and as a consequence, two of its abandoned projects have made the list of top downgrades of the past 12 months. Meanwhile, there was another big upgrade for Novartis' heart failure therapy LCZ696, which looks set to be a future blockbuster.

    Comment?

  9. While Mylan and Teva Continue Bickering, Perrigo Snaps Up OTC Portfolio From GlaxoSmithKlineRead the original story

    Jun 1, 2015 | BioSpace

    ... to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis International AG ("Novartis"). Perrigo will acquire the following assets in an all-cash transaction in which the purchase price ...

    Comment?

  10. Perrigo To Acquire Portfolio Of Leading OTC Brands From GlaxoSmithKlineRead the original story

    Jun 1, 2015 | BioSpace

    ... to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis International AG ("Novartis"). Perrigo will acquire the following assets in an all-cash transaction in which the purchase price ...

    Comment?

  11. Perrigo To Acquire Portfolio Of Leading OTC Brands From GSKRead the original story

    Jun 2, 2015 | Sys-Con Media

    Perrigo will acquire the following assets in an all-cash transaction in which the purchase price was not disclosed. Several assorted OTC brands including Coldrex across the EEA, and Panodil , Nezeril , and Nasin in Novartis's legacy cold sore management products primarily in the EEA, marketed under the brand names Vectavir, Pencivir, Fenivir, Fenlips and Vectatone.

    Comment?

  12. Novartis AG Upgraded to "Buy" at VontobelRead the original story

    May 26, 2015 | AmericanBankingNews.com

    Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Novartis AG from a "hold" rating to a "sell" rating and set a $102.00 price target on the stock in a research note on Wednesday, March 25th.

    Comment?

  13. Complete List of Pharmaceutical Companies with the Highest RevenueRead the original story w/Photo

    May 14, 2015 | Money Morning

    ... billion of that total according to the research firm Statista . The list of pharmaceutical companies is topped by Novartis AG (NYSE: NVS ), which had more than $51 billion in pharmaceutical revenue in 2014. The $274 billion company's biggest revenue ...

    Comment?

  14. Glaxo Q1 Earnings Miss, But 5-Year Guidance StrongRead the original story w/Photo

    May 6, 2015 | Investor's Business Daily

    ... 2015 earnings are off due to the dilutive effect of its massive asset swap with (NYSE: NVS ), in which Glaxo bought Novartis' vaccines for $7.1 billion while Novartis acquired Glaxo's cancer business for $14.5 billion. Glaxo also canceled plans to ...

    Comment?

  15. Novartis Pharms. Corp. v. Mylan Inc.Read the original story w/Photo

    Apr 28, 2015 | JD Supra

    Case Name: Novartis Pharms. Corp. v. Mylan Inc., Civ. No. 14-777-RGA, 2015 U.S. Dist.

    Comment?

  16. Novartis Pharmaceuticals Corporation is First Company to Receive...Read the original story

    Apr 27, 2015 | CSRwire.com

    Novartis Pharmaceuticals Corporation has been named the top company for diversity for the second year in a row on the annual DiversityInc Top 50 Companies for Diversity listing. DiversityInc announced the results of its 2015 Top 50 Companies for Diversity on April 23 at an awards ceremony in New York, NY.

    Comment?

  17. Novartis Posts Higher Q1 ProfitRead the original story

    Apr 23, 2015 | Benzinga

    Novartis AG reported a rise in its net income for the first quarter and reiterated its outlook for the full year. The company posted quarterly net income of $13.01 billion, or $5.40 per share, compared to $2.97 billion, or $1.21 per share, in the year-earlier period.

    Comment?

  18. Our 2 Healthcare Picks For AprilRead the original story w/Photo

    Apr 14, 2015 | Seeking Alpha

    ... by the company's COPD and asthma franchises, which are expected to offer significant sales potential. So while Novartis' (NYSE: NVS ) respiratory drugs Arcapta/Onbrez continue to eat away at GSK's bottom line, we believe GSK's strong pipeline will ...

    Comment?

  19. Bought iShares MSCI United Kingdom ETFRead the original story w/Photo

    Apr 13, 2015 | Seeking Alpha

    ... any bond overlap between a fund and an individual bond holding. For example, I have a significant position in Novartis (NYSE: NVS ), discussed in this SA Instablog . I also have a significant position in the Swiss Helvetia Fund ( SWZ ) that has a ...

    Comment?

  20. IPO-bound Bay Area biotech snags Big Pharma cancer dealRead the original story w/Photo

    Mar 30, 2015 | Business Journal

    Tiny Aduro Biotech Inc. hopes to put the STING on cancer with a potential $750 million deal between the Berkeley company and drug giant Novartis AG. The deal centers on experimental synthetic small molecules, developed by Aduro, that could be the latest weapon in the hot field of cancer immunotherapy.

    Comment?